Match Document Document Title
DE102018124022A1 HYALURONIC ACID STABILIZER  
The ITIH5 mammalian protein is disclosed as a stabilizer of hyaluronic acid or a salt thereof. A composition is also provided which contains the ITIH5 mammalian protein and water. An in vitro...
DE102019120667A1 Dosing scheme for BCMAxCD3 antibody constructs  
The present invention relates to an antibody construct comprising a first domain that binds to BCMA and a second domain that binds to CD3 for use in treating or ameliorating a BCMA positive...
DE102018107224A1 Peptides and combinations of peptides of non-canonical origin for use in immunotherapy against various cancers  
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic procedures. In particular, the present invention relates to the immunotherapy of cancer....
DE112017005457T5 FC AREA OF AGLY COSMATED ANTIBODIES FOR CANCER TREATMENT  
The present disclosure relates to a polypeptide containing an Fc domain in which a part of an amino acid sequence of a human Fc domain of a human antibody having a different amino acid sequence is...
DE102017125888A1 New engineered T cell receptors and their use in immunotherapy  
The present invention relates to antigen-recognizing constructs against COL6A3 antigens. In particular, the invention provides novel engineered T cell receptor (TCR) based molecules which are...
DE112017002105T5 Method for the determination of DPP3 and therapeutic methods  
The present invention relates to methods for the determination of active DPP3 in a body fluid sample, an assay or kit for the determination of active DPP3 in a body fluid sample, a method for...
DE102017115966A1 Polypeptide molecule with improved dual specificity  
The present invention relates to a bispecific polypeptide molecule, comprising a first polypeptide chain and a second polypeptide chain, which provide a binding region, derived from a T cell...
DE102018004759A1 Diagnosis of a neuroautoimmune disease  
The present invention relates to a method for diagnosing a disease, comprising the step of detecting an antibody that binds to a polypeptide selected from the group comprising NSF, STX1B and VAMP2...
DE102017207049A1 Cell-free combination, hydrogel-like material or hydrogel and uses thereof  
The invention relates to a cell-free combination for use - in the controlled, in particular slowed or delayed, drug release and or in the preparation of a hydrogel-like formulation, in particular...
DE102017003725A1 Anti-VEGF and anti-C5 antibodies for the treatment of equine recurrent uveitis  
The invention relates to the use of antibodies directed against VEGF or C5 for the treatment of equine recurrent uveitis (ERU) as well as suitable pharmaceutical compositions for the treatment...
DE102017001875A1 Drug for malignant treatment  
Methods are disclosed for providing a medicament for treating a malignancy involving the individually associated immune system, antibodies provided thereby, and their use, wherein the individual...
DE202015009619U1 Pharmaceutical anti-TNFα antibody formulation  
Pharmaceutical formulation, which is free from a phosphate buffer and is selected from the group consisting of: (a) a liquid, aqueous pharmaceutical formulation comprising a therapeutically...
DE102011008153B4 Process for the preparation of a monoclonal antibody against oligomeric alpha-synuclein  
A method for producing a monoclonal antibody against pathological oligomeric alpha-synuclein by Immunization of mice or in vitro cell cultures with the peptide TKEGWHGVATVAE of the...
DE212016000236U1 Human endothelin receptor binding antibody and its use  
A specifically binding to human endothelin receptors antibody, characterized in that the antibody comprises one of the following schemes of amino acid sequences: a. CDR3 light chain sequence...
DE112016004398T5 THE ANTIBODIES THAT SPECIFICALLY BIND THE TYPE-1 RECEPTOR OF THE FIBROBLAST GROWTH FACTOR, THE USE OF ANTIBODIES FOR THE TREATMENT OF ONCOLOGICAL DISEASES, A PROCESS FOR THE MANUFACTURE OF THE ANTIBODIES  
The group of inventions relates to biotechnology and medicine and refers to antibodies for the treatment of oncological diseases. The antibodies of the invention specifically bind and block...
DE202015009509U9 Pharmaceutical anti-TNFα antibody formulation  
Pharmaceutical formulation that is free of a phosphate buffer and selected from the group consisting of: (a) a liquid, aqueous pharmaceutical formulation comprising a therapeutically effective...
DE202015009509U1 Pharmaceutical anti-TNFα antibody formulation  
Pharmaceutical formulation, which is free from a phosphate buffer and selected from the group consisting of: (a) a liquid, aqueous pharmaceutical formulation comprising a therapeutically effective...
DE102011118022B4 Antibodies against the prostate-specific stem cell antigen and its use  
The invention relates to recombinant antibodies that bind to prostate-specific stem cell antigen (PSCA). The antibody according to the invention contains complementarity-determining regions (CDR)...
DE112016001013T5 ANTIBODIES, USES AND METHODS  
The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
DE102017110958A1 Pharmaceutical compositions with anti-RANKL antibodies, calcium and vitamin D, suitable for the treatment and / or prophylaxis of diseases of the bone metabolism and of therapy-related hypocalcemia  
The present invention includes pharmaceutical compositions comprising anti-RANKL antibodies, calcium and vitamin D, which are suitable for the treatment and / or prophylaxis of diseases of the...
DE102016106510A1 Method and device for extracorporeal removal of pathogenic and / or surplus components from a cell sample of a patient  
The invention relates to a method for extracorporeal removal of pathogenic and / or surplus components from a cell sample of a human or animal patient suffering from a disease. The method...
DE202017003228U1 Enrichment of eggs with vitamin K and avian immunoglobulins  
A first subject of the invention relates to the use of natto for the preparation of a veterinary drug or feed for the enrichment of vitamin K (particularly menaquinones-7 (MK-7) in animal foods,...
DE102016105449A1 Bifunctional prodrugs  
In a first aspect, the present invention is directed to new compounds, more specifically to new bifunctional prodrugs and drugs. In a further aspect, the present invention is directed to...
DE102016103562A1 Pharmaceutical agents for use in the treatment of amyotrophic lateral sclerosis (ALS) and diagnostic procedures  
The invention relates to pharmaceutical active ingredients for use in the treatment of amyotrophic lateral sclerosis (ALS) and diagnostic methods for ALS.
DE202016104050U1 IGM antibody, composition and kit containing this antibody for the treatment or diagnosis of a disease  
An IgM antibody for use in a method for treating or diagnosing a disease in a subject which disease can not be treated or diagnosed with an IgG antibody having at least comparable specificity.
DE112015001085T5 Antibodies, uses and procedures  
The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
DE19819846B4 Multivalent antibody constructs  
Multivalent FvAntibodies with at least four variable domains which are linked to one another via a peptide linker 1, a mean peptide linker 2 and a peptide linker 3, characterized in that the...
DE202012013369U1 Fertile transgenic animals, useful for producing antibodies that carry human variable regions  
IV bag (infusion bag), or container connected to an IV syringe, containing a pharmaceutical composition comprising an antibody and a diluent, an excipient or a carrier, wherein the antibody is...
DE202015009007U1 Targeting human PCSK9 for cholesterol treatment  
Antibody or antibody fragment for use in a method of reducing cholesterol or maintaining a previously reduced cholesterol level in a human in need, the method comprising administering the antibody...
DE202015009006U1 Targeting human PCSK9 for cholesterol treatment  
An antibody or antibody fragment for use in a method of reducing or maintaining a previously reduced cholesterol level in a human in need, the method comprising administering the antibody or...
DE202015009002U1 Targeting human PCSK9 for cholesterol treatment  
An antibody or antibody fragment for use in a method of reducing or maintaining a previously reduced cholesterol level in a human in need, the method comprising administering the antibody or...
DE102015102094A1 Immunosuppressant for use in a method of treating gingivitis or periodontitis and Pharmaceutical Composition  
Periodontitis is a caused by bacteria chronic inflammatory disease that has a largely irreversible destruction of the gums result. To combat the inflammation treatment is complemented by the use...
DE202015008988U1 Targeting human PCSK9 for cholesterol treatment  
Antibody or antibody fragment for use in a method of reducing cholesterol or maintaining a previously reduced cholesterol level in a human in need, the method comprising administering the antibody...
DE202015008974U1 Targeting human PCSK9 for cholesterol treatment  
Antibody or fragment of a body for use in a method of reducing cholesterol or maintaining a previously reduced level of cholesterol in a human in need thereof, the method comprising administering...
DE19616486C5 Method of lowering blood glucose in mammals  
Oral use of inhibitors of dipeptidyl peptidase (DP IV) enzyme activity without additional administration of exogenous insulinotropic peptides GIP1-42, GLP-17-36 or their analogues, for lowering...
DE202015009016U1 Pharmaceutical anti-TNFα antibody formulation  
Pharmaceutical formulation that is free or substantially free of a phosphate buffer and selected from the group consisting of: (a) a liquid, aqueous pharmaceutical formulation comprising a...
DE102014013571A1 Monoclonal antibody to human TAU protein  
The present invention relates to the monoclonal antibody 1G2, the hybridoma H-1G2, characterized by DSM ACC3248 and the epitope TPP comprising the amino acids tryptophan, proline, proline....
DE202014010421U1 Human goals  
A human anti-VEGF-A ligand for use in a method of treating or reducing the risk of retinopathy in a human comprising administering the ligand to humans, the human anti-VEGF-A ligand being specific...
DE202008018562U1 Antigen-binding proteins against proprotein convertase subtilisin kexin type 9 (PCSK9)  
Monoclonal antibody or fragment thereof that competes for binding to PCSK9 with: (a) an antibody comprising a heavy chain variable region of the amino acid sequence as set forth in SEQ ID NO: 49;...
DE202014010499U1 Targeting human PCSK9 for cholesterol treatment  
An antibody or antibody fragment for use in reducing cholesterol or maintaining a previously reduced cholesterol in a person in need thereof, the antibody comprising a VH domain generated by...
DE102014206881A1 Process for the purification of natural cytotoxic IgM antibodies  
The present invention relates to a preparation of cytotoxic IgM antibodies which is essentially free of non-cytotoxic IgM antibodies and of antibodies of other classes, a method for producing such...
DE102013227106A1 In-vitro method for diagnosing an active lupus nephritis  
The present invention describes a method for in vitro diagnosis of active lupus nephritis, with CD4 + CD69 + T cells are detected in a sample of a test subject.
DE102013111487A1 The bispecific antibody fragment and pharmaceutical combination preparation with such a  
The invention relates to a bispecific antibody fragment (10) with a first detection point (12) and at least a second detection point (14), which specifically recognize each at least one structure...
DE102013105144A1 The pharmaceutical combination product with an anti-idiotype antibody fragment  
The invention relates to a pharmaceutical combination preparation (10), in particular to suppression of an immune response, preferably a humoral immune response against a therapeutic organism...
DE102010039019B4 Antibodies against 6-sulfo LacNAc positive human dendritic cells and their use  
Composition, comprehensive a) at least one anti-slan antibody which specifically binds to human dendritic cells whose surface has the P selectin glycoprotein ligand 1 (PSGL-1) with the O-linked...
DE212011100195U9 Antibody that stops or delays tumor growth (variants)  
Monoclonal antibody with a hypervariable 1-3 CDR section according to SEQ ID NO: 1 and / or 2 and / or 3, which has an affinity of at least 2 × 10–9 to domains II and IIIc of fibroblast growth...
DE112012000439T5 Stem cell factor inhibitor  
Herein methods, compositions and uses with respect to the inhibitor of stem cell factor are provided. There are, for herein. B. antibodies provided responsive to target the stem cell factor for...
DE202014002699U1 Pharmaceutical composition for the treatment of burnout syndrome  
Composition or kit-of-parts comprising or consisting of a) at least one ingredient comprising a vitamin mixture; and b) a component comprising an IgG antibody, the vitamin mixture comprising...
DE10329087B4 Microspheres containing antigens for allergy therapy  
Microspheres for allergy therapy, which contain antigens and / or DNA of antigens, characterized in that the microspheres have a binding constant KB of at least 1 × 104 M–1 compared to the...
DE102008033381B4 Modulation of the immune response by the receptor NKp65 and its ligands  
Use of a substance for blocking the NKp65 receptor for the manufacture of a medicament for the treatment and / or prevention of inflammatory and autoimmune diseases, in particular the skin, the...